Latest news

• NICE publishes draft guidance recommending three COVID-19 treatments

  Those not recommended at this stage are Regenerons’ casirivimab and imdevimab, Merck and Ridgeback’s molnupiravir, GSK and Vir Biotechnology’s sotrovimab, as well as Gilead's remdesivir and AstraZeneca’s

• Merck and Ridgeback fulfil US deal for molnupiravir

  Merck &Co – known as MSD outside the US and Canada – and Ridgeback Biotherapeutics have announced that approximately 3.1 million courses of its investigational oral antiviral COVID-19 treatment, molnupiravir, have ... Speaking on behalf of Ridgeback

• US regulators set to approve oral antiviral against COVID-19

  Merck developed molnupiravir with Ridgeback Biotherapeutics. “With the continued spread of the virus and the emergence of variants, additional treatments for COVID-19 are urgently needed,” said Dr Dean Y Li,

• UK’s MHRA approves first oral antiviral against COVID-19

  The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has become the first regulatory agency to approve Lagevrio ( molnupiravir), developed by Ridgeback Biotherapeutics and Merck &Co – known as MSD outside

• Merck’s COVID-19 antiviral under review in Europe by EMA

  The European Medicines Agency (EMA) has started a rolling review of molnupiravir, the oral antiviral developed by Merck &Co – known as MSD outside the US and Canada – and partner Ridgeback Biotherapeutics ... an oral antiviral medicine that can be